Fubotv earnings beat by $0.10, revenue topped estimates
Apimeds Pharmaceuticals US, Inc. (NYSE American:APUS), a pharmaceutical company with a market capitalization of $20.71 million and currently trading at $1.79, has announced on Monday the extension of the maturity dates for three of its outstanding promissory notes. According to InvestingPro analysis, the company operates with moderate debt levels but maintains a weak financial health score. The amendments to the terms of these notes were agreed upon with Inscobee Inc. and Apimeds Inc., also known as Apimeds Korea.
The original promissory notes were issued to Inscobee Inc. on May 20, 2024, and August 19, 2024, in the principal amounts of $100,000 and $150,000, respectively. Another note was issued to Apimeds Korea on March 31, 2025, with a principal amount of $250,000. With a current ratio of 0.01, InvestingPro data shows the company’s short-term obligations exceed its liquid assets. Prior to the amendments, the May and August 2024 notes were due on the earlier of May 19, 2025, or upon the closing of an equity financing by the company with gross proceeds of at least $3,000,000. The March 2025 note was due on the earlier of December 31, 2026, or upon the company’s common stock being listed for trading on the NYSE American or another national securities exchange.
The amendments have extended the maturity dates of all three notes to May 19, 2026. The interest rate remains at 5% per annum, and the payment under each note is due within five days of maturity. Based on InvestingPro’s Fair Value analysis, the stock appears to be trading above its intrinsic value. Unlock 6 additional key insights and comprehensive financial metrics with an InvestingPro subscription.
The company’s decision to extend the maturity dates of these promissory notes provides it with more financial flexibility moving forward. The full details of the amendments can be found in the form of the Amendment, which is filed as Exhibit 10.1 to the Current Report on Form 8-K and is incorporated by reference.
This financial maneuver by Apimeds Pharmaceuticals US, Inc. is based on information contained in a recent SEC filing.
In other recent news, Apimeds Pharmaceuticals has made its debut on the New York Stock Exchange, with shares priced at $4 each, aligning with its initial public offering (IPO) price. The company successfully sold 3,375,000 shares of common stock, anticipating gross proceeds of $13.5 million before accounting for underwriting discounts and other related expenses. Apimeds has also granted underwriters a 45-day option to purchase an additional 506,250 shares at the public offering price, excluding discounts. Furthermore, the company has issued warrants to the underwriters, permitting the purchase of up to 168,750 shares of common stock, a figure that could rise to 194,063 shares if the over-allotment option is fully exercised. These warrants are exercisable over four and a half years, starting 180 days after the offering’s closure. D. Boral (OTC:BOALY) Capital LLC is serving as the sole book-running manager for this offering. These recent developments are part of Apimeds’ strategic financial activities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.